TWI292319B - Application of the prepraration of cimicifuga racemosa - Google Patents
Application of the prepraration of cimicifuga racemosa Download PDFInfo
- Publication number
- TWI292319B TWI292319B TW090126157A TW90126157A TWI292319B TW I292319 B TWI292319 B TW I292319B TW 090126157 A TW090126157 A TW 090126157A TW 90126157 A TW90126157 A TW 90126157A TW I292319 B TWI292319 B TW I292319B
- Authority
- TW
- Taiwan
- Prior art keywords
- application
- urinary incontinence
- treatment
- preparation
- extract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
1292319 " A7 __ B7__ 五、發明說明() 本發明關於一種黑蛇根草(Cimicifuga racemosa,德: Trauben silberkerze (葡萄銀燭),英:black cohosh 或 black snakeroot)的應用,特別是一種萃取物,且尤其是來自其 根株系(Wurzelstock,英:r〇〇t stock )(黑蛇根草根莖 Rhizomacimicifugaeracemosae)之萃取物的應用。 黑蛇根草的萃取物係在婦科用於治療更年期病痛( Wechseljahresbeschwerde,英:climateric complaint),如: 熱主動性充血(Hitzewallung,英:heat active congestion) 、汗暴發(Schwefiausbruch )、睡眠障礙、神經過敏( NervositSt)及抑醫性情緒不佳(depressive Verstimmung, 英:depressive emotional deterioration)的狀態。這種萃取 物可做爲雌性激素(動情激素)(Oestrogen英:estrogen )的替代治療。在對抗療法(allopathisch)的動物醫藥中 ,黑蛇根草的萃取物則未扮演重要角色。 出乎意料地,茲發現黑蛇根草的製劑在有尿失禁( Harninkontinenz)的場合具有治療效果。 人們知道,母狗在閹割後,亦即除去卵巢後(可能還 包含子宮)平均約在卵巢子宮切除手術(〇vari〇-Hysterektomie)後約2.7年有約20%會有尿失禁的手術後 遺症。今日,這種疾病徵象主要利用擬交感神經藥物( Sympathomimetika)治療,但這些藥物在動物未作最佳控 制的場合會引起大幅的副作用。 在稍早人們猜想:該尿失禁要歸咎於由於手術( Eingriff)造成的雌性激素缺乏(〇estr〇gendefizienz)。儘 3 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公^ ) -- I —ί—I*-----裝--------訂-------- (請先閱讀背面之注意事項再填寫本頁) 1292319 A7 _:_B7__ 五、發明說明(1 ) 管對於這種因果關係有疑問(它是在卵巢切除手術後平均 2.7年因出現症狀而被注意),人們仍試著利用雌性激素替 代法以治療這種病徵。這種疑問以及治療時發生的副作用 ,使得人們日益將使用擬交感神經藥物的治療列入考慮。 即使在基本失禁發生率(basale Inkontinenzinzidenz) 本來爲10〜33%的六十歲以上的婦女的場合,如果作子宮 切除,亦即除去子宮而不除去卵巢(換言之,這種手術對 荷爾蒙狀況沒有額外的影響),也會使發展成尿失禁的或 然料增加到60%。討論這種關係的原因,係認爲是骨盆部 位的神經與韌帶結締組織構造受手術影響造成的病竈( Lasion,英:lesion) [ Lancet 2000 ; 356 ( 9229) : 535〜 539〕。即使在獸醫學的典型手術方式的場合,也都有同類 的病竈。因此,依本發明用於治療尿失禁的黑蛇根草的製 劑的效果並不在於迄今有關蛇根所述的性質〔作爲雌性激 素替代物或作爲具有內分泌活性的植物療法藥物( Phytotherapeutikum)〕,反而是在於這些習知性質以外的 效果。 雖然人們會想到獸醫學上的因果及治療檢查結果( Befund,英:finding)可能可以轉用到人類醫學的症狀徵 候群上,但這種發現的結果也可推想及在卵巢切除或絕經 期間(perimenopausal)或絕經期後(postmenopausal)的 婦女治療尿失禁的效果。在絕經期後的婦女,尿失禁的發 生率在20〜50%之間依年齡而定。在絕經期間則未見增加 。一種早先的雌性激素(女性荷爾蒙)的替代藥物只能將 4 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) U—^ l·---------------^--------- (請先閱讀背面之注音?事項再填寫本頁) 1292319 I , , , ;···^| a7 1 .. 〜j R7_ 五、發明說明($ ) 症狀作小小而短期內的改善,但在長時間中在超過60歲的 婦女發現尿失禁的危險增加,這點在一項硏究〔D. H. Thom, J. S. Brown in J Am Geriatr Soc 1998 ; 46(11) : 1411 〜1417〕發表過。 因此迄今的背景知識並未能予人啓示想到依本發明應 用黑蛇根草來治療尿失禁,更別提它的出色效果了。 依本發明的應用,所求出之有效的每日劑量爲一種藥 物含量〇·1〜10mg/每公斤體重。因此在錠劑形式中的萃 取物的藥物含量宜配成5〜200mg間,且宜配製成10〜 50mg/每粒錠劑。 依本發明所用之萃取物宜利用一種醇式萃取劑(特別 是用乙醇、異丙醇、及甲醇)製造。 施(月艮)用方式(Verabreichung ,英:administration )可用所有通用的施用形式,例如呈顆粒、膠囊(Kapsel )、栓劑(Suppositorie )、錠劑、溶劑、浸(煎)劑製造 (Teezubereitung ’ 英:tea preparation)或具有石膏的皮 膚滲透藥劑(transdermal)或類似物。 也可考慮將之混在食品或動物飼料中。 此製劑不一定須呈萃取物形式施用。舉例而言,也可 將該植物磨粉或植物的部分直接或間接——例如像茶一樣 冲泡--而服用。 用本發明之黑蛇根草製劑的治療特別可用於在卵巢子 宮切除後的雌性動物以及用於子宮切除後或絕經後的婦女 〇 5 (請先閱讀背面之注意事項再填寫本頁) ▼裝--------訂---- I H ·1 ϋ 1 拳
Ur 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A7 1292319 __ B7____ 五、發明說明(Zp ) 〔實例〕 在具有尿失禁症狀的切除卵巢的母狗利用錠劑形式的 黑蛇根草根株(Rhizoma cimicifugae racemosae)治療( Schaper & Brtimmer 公司的 “Remifemin” 錠劑)。所用之 有效之每日劑量爲半粒〜一粒錠劑/每10公斤體重。在所 做的四十個案例中,都使尿失禁情形緩解(Remission)。 病犬主人對治療效果及藥物相容性的主觀感覺是完全正面 的。在所有情形中都要求繼續治療。在所有情形中,情況 都明顯改善到完全治療。 使用之Remifemin錠劑含有萃取物係20mg藥劑/每 粒錠劑。所用萃取劑爲異丙醇40%體積。 (請先閱讀背面之注意事項再填寫本頁) tr--------- 6 本紙張尺度適用中國國家標準(CNS)A4規格(21〇 X 297公爱)
Claims (1)
1292319 φ…:…: C8 V人-… D8 六、申請專利範圍 | 顆 1 · 一種來自黑蛇根草(cimicifuga racemosa)的製 .劑的應用,其係用於製造治療尿失禁的藥劑者。 2 ·如申請專利範圍第1項的製劑的應用,其係爲黑 蛇根草之醇式萃取物。 3 ·如申請專利範圍第1項的製劑的應用,其係爲 40%體積之異丙醇萃取物。 4 ·如申請專利範圍第2或第3項的製劑的應用,其 藥物含量在5〜200mg/每錠劑之間。 5 ·如申請專利範圍第1項的製劑的應用,其係呈混 在一種動物飼料中的混合成份。 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10054641A DE10054641A1 (de) | 2000-11-03 | 2000-11-03 | Verwendung einer Zubereitung von Cimicifuga racemosa |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI292319B true TWI292319B (en) | 2008-01-11 |
Family
ID=7662102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090126157A TWI292319B (en) | 2000-11-03 | 2001-10-23 | Application of the prepraration of cimicifuga racemosa |
Country Status (9)
Country | Link |
---|---|
US (1) | US6713097B2 (zh) |
EP (1) | EP1330255B1 (zh) |
JP (1) | JP2004512368A (zh) |
AT (1) | ATE297747T1 (zh) |
AU (2) | AU2002218143B2 (zh) |
DE (2) | DE10054641A1 (zh) |
ES (1) | ES2240554T3 (zh) |
TW (1) | TWI292319B (zh) |
WO (1) | WO2002036140A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL150650A0 (en) | 2000-01-20 | 2003-02-12 | Eisai Co Ltd | Piperidine derivatives and pharmaceutical compositions containing the same |
DE10146159A1 (de) * | 2001-09-19 | 2003-04-10 | Bionorica Ag | Verwendung von Extrakten aus Cimicifuga-Arten als organselektives Arzneimittel zur Behandlung von sexualhormonabhängigen Erkrankungen des Urogenitaltraktes |
US7060304B2 (en) * | 2003-04-16 | 2006-06-13 | Access Business Group International Llc | Skin whitening compositions containing black cohosh extract |
US6994874B2 (en) * | 2003-04-16 | 2006-02-07 | Access Business Group International, Llc | Skin whitening compositions containing asparagus extract |
EP2545932A1 (de) | 2011-07-12 | 2013-01-16 | Bionorica Se | Ausgewählte Cimicifuga-Fraktionen zur Behandlung von Osteoporose |
WO2013007807A1 (de) | 2011-07-12 | 2013-01-17 | Bionorica Se | Ausgewählte cimicifuga-fraktionen zur behandlung von osteoporose |
EP2620155A1 (de) | 2012-01-30 | 2013-07-31 | Bionorica SE | Arzneimittel enthaltend Cimicifuga zur Anwendung bei der Behandlung von Sarkopenie und Herzmuskelschwäche |
US20150313956A1 (en) * | 2014-05-05 | 2015-11-05 | Napier Consulting Llc | Compositions and methods for hair growth |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19652183C1 (de) * | 1996-12-14 | 1998-02-12 | Schaper & Bruemmer Gmbh | Verwendung eines Extraktes aus Cimicifuga racemosa |
DE19812204A1 (de) | 1998-03-19 | 1999-11-04 | Plantamed Arzneimittel Gmbh | Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung |
-
2000
- 2000-11-03 DE DE10054641A patent/DE10054641A1/de not_active Withdrawn
-
2001
- 2001-10-12 DE DE50106546T patent/DE50106546D1/de not_active Expired - Lifetime
- 2001-10-12 AU AU2002218143A patent/AU2002218143B2/en not_active Ceased
- 2001-10-12 EP EP01992579A patent/EP1330255B1/de not_active Expired - Lifetime
- 2001-10-12 WO PCT/DE2001/003926 patent/WO2002036140A2/de active IP Right Grant
- 2001-10-12 AT AT01992579T patent/ATE297747T1/de active
- 2001-10-12 US US10/239,888 patent/US6713097B2/en not_active Expired - Fee Related
- 2001-10-12 JP JP2002538951A patent/JP2004512368A/ja active Pending
- 2001-10-12 ES ES01992579T patent/ES2240554T3/es not_active Expired - Lifetime
- 2001-10-12 AU AU1814302A patent/AU1814302A/xx active Pending
- 2001-10-23 TW TW090126157A patent/TWI292319B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE50106546D1 (de) | 2005-07-21 |
US20030049340A1 (en) | 2003-03-13 |
WO2002036140A3 (de) | 2002-09-19 |
WO2002036140A2 (de) | 2002-05-10 |
DE10054641A1 (de) | 2002-05-16 |
EP1330255B1 (de) | 2005-06-15 |
AU1814302A (en) | 2002-05-15 |
ATE297747T1 (de) | 2005-07-15 |
AU2002218143B2 (en) | 2005-07-21 |
US6713097B2 (en) | 2004-03-30 |
ES2240554T3 (es) | 2005-10-16 |
JP2004512368A (ja) | 2004-04-22 |
EP1330255A2 (de) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW403649B (en) | Estrogen agonists as remedies for prostate diseases and obesity | |
Brown et al. | Progestagens and anti‐progestagens for pain associated with endometriosis | |
Mahboubi | Foeniculum vulgare as valuable plant in management of women's health | |
JPS61178917A (ja) | 抗エストロゲンと担体よりなる組成物の製法 | |
JP2002522391A (ja) | 前立腺配合物 | |
Parkes et al. | Interruption of Early Pregnancy by Orally Active Oestrogens | |
Shahin et al. | Adding phytoestrogens to clomiphene induction in unexplained infertility patients–a randomized trial | |
TWI292319B (en) | Application of the prepraration of cimicifuga racemosa | |
JP2018512450A (ja) | 女性の性的障害を治療するための化合物及び剤型 | |
Cagnacci et al. | Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri-and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE) | |
JP2013199506A (ja) | 処置方法 | |
TWI280877B (en) | Beta-agonists for treating endometriosis or infertility, or improving fertility | |
JP4362442B2 (ja) | 女性における萎縮の抑制方法または萎縮関連症状の治療または予防方法 | |
Miller | Alternatives to estrogen for menopausal symptoms | |
Kenemans | Tibolone: how does its mechanism of action translate into clinical effects | |
Shubhashree et al. | Ayurvedic management of uterine fibroids: a case report | |
Stearns | Management of hot flashes in breast cancer survivors and men with prostate cancer | |
Shubhashree et al. | Successful management of uterine fibroids by Ayurvedic treatment | |
Mehra et al. | Managing endometrial calcifications using Kshara Taila and Phalaghrita Uttara Basti: a case report | |
Qing et al. | Comparison of oral dydrogesterone and intramuscular progesterone in the treatment of threatened abortion | |
US20070028930A1 (en) | Active agent and formulations to minimize or alleviate bladder urgency and irritation and/or to enhance sexual function | |
Kalentzi et al. | Safety of vaginal oestrogen in postmenopausal women | |
Nieto et al. | Evaluation of gestrinone after surgery in treatment of endometriosis | |
Yu et al. | Effect of mifepristone and lithospermum combination regimen on medical abortion in early pregnancy rats | |
Patel et al. | Menopause and hormone replacement therapy: what is the future |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |